A New Weekly Injection Cut Repeat Blood Draws for Most Patients with a Rare Blood Cancer

FDA approved Mimrylo for polycythemia vera. In trial data, 76.9% of patients needed no blood draws during weeks 20 to 32, versus 32.9% on placebo.

Have A Referral?